Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23382438 | 0.80 | HDAC1 (0.46) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL6489306 | 0.80 | DRD2 (0.39) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL6489300 | 0.79 | DRD4 (0.38) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL5847660 | 0.79 | EGFR (0.41) | DRD4DRD3DRD2HDAC1MIF | |
| Hydrochloric Acid SCHEMBL38663344 | 0.77 | EGFR (0.41) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL1780171 | 0.76 | HDAC1 (0.46) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL24415150 | 0.76 | HDAC1 (0.38) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL23382439 | 0.76 | MIF (0.43) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL15742623 | 0.76 | PDE5A (0.38) | DRD4DRD3DRD2HDAC1MIF | |
| SCHEMBL16740123 | 0.75 | HTR2C (0.32) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | EISAI CO.LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1555265-A1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | Eisai Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | DRD4 4680/4885DRD3 4478/4885DRD2 4710/4885 |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | CRHR1, MC2R, CRH | DRD4 71/4885DRD3 109/4885DRD2 81/4885 |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | MC2R, CRHR1, CRHR2 | DRD4 70/4885DRD3 128/4885DRD2 91/4885 |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | DRD4 4680/4885DRD3 4478/4885DRD2 4710/4885 |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | CYP4F3, CYP4F2, CYP2F1 | DRD4 173/4885DRD3 117/4885DRD2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.